Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry
Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL
The Journal of clinical psychiatry · 412 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Mental Health
- Gobierno
- National Center for Complementary and Integrative Health
- Gobierno
- NIMH NIH HHS
- Gobierno
- NCCIH NIH HHS
- Subvenciones
- National Center for Complementary and Integrative Health (5K23AT001129-05); National Institute of Mental Health (5K23MH066265)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2006-12-15 · J Clin Psychiatry · vol. 67 · número 12 · págs. 1954–1967
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 708 citas · más que el 100% de estudios similares · 40.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 118 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Treatment of Major Depression · Tryptophan and brain disorders
- Palabras clave
- omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, major depressive disorder, bipolar disorder, schizophrenia, borderline personality disorder, attention deficit hyperactivity disorder, dementia, mood disorders, dietary supplementation, evidence-based treatment recommendations
- MeSH
- humans, fatty acids, omega-3, epidemiologic studies, mental disorders, tissue distribution
11 autores
- Marlene P. Freeman🇺🇸University of Arizona
- Joseph R. Hibbeln🇺🇸National Institutes of Health
- Katherine L. Wisner🇺🇸University of Pittsburgh
- John M. Davis🇺🇸University of Maryland, Baltimore; University of Illinois Chicago
- David Mischoulon🇺🇸Harvard University
- Malcolm Peet🇬🇧University of Sheffield
- Paul E. Keck🇺🇸University of Cincinnati
- Lauren B. Marangell🇺🇸United States Department of Veterans Affairs; Baylor College of Medicine
- Alex J. Richardson🇬🇧University of Oxford
- James Lake🇺🇸Stanford University
- Andrew L. Stoll🇺🇸Harvard University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To determine if the available data support the use of omega-3 essential fatty acids (EFA) for clinical use in the prevention and/or treatment of psychiatric disorders.
Participants
The authors of this article were invited participants in the Omega-3 Fatty Acids Subcommittee, assembled by the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA).
Evidence
Published literature and data presented at scientific meetings were reviewed. Specific disorders reviewed included major depressive disorder, bipolar disorder, schizophrenia, dementia, borderline personality disorder and impulsivity, and attention-deficit/hyperactivity disorder. Meta-analyses were conducted in major depressive and bipolar disorders and schizophrenia, as sufficient data were available to conduct such analyses in these areas of interest.
Consensus process
The subcommittee prepared the manuscript, which was reviewed and approved by the following APA committees: the Committee on Research on Psychiatric Treatments, the Council on Research, and the Joint Reference Committee.
Conclusions
The preponderance of epidemiologic and tissue compositional studies supports a protective effect of omega-3 EFA intake, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in mood disorders. Meta-analyses of randomized controlled trials demonstrate a statistically significant benefit in unipolar and bipolar depression (p = .02). The results were highly heterogeneous, indicating that it is important to examine the characteristics of each individual study to note the differences in design and execution. There is less evidence of benefit in schizophrenia. EPA and DHA appear to have negligible risks and some potential benefit in major depressive disorder and bipolar disorder, but results remain inconclusive in most areas of interest in psychiatry. Treatment recommendations and directions for future research are described. Health benefits of omega-3 EFA may be especially important in patients with psychiatric disorders, due to high prevalence rates of smoking and obesity and the metabolic side effects of some psychotropic medications.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.